NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and ...
NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and ...
Y-mAbs announces positive Phase 1 Trial 1001 results for GD2-SADA in cancer, plans further studies with optimized radiohapten "Proteus." Y-mAbs Therapeutics, Inc. announced positive results from the ...
Y-mAbs is a commercial-stage biotech, and its one commercialized product, Danyelza, brought in $22.8 million for the second quarter and was responsible for all the company's net revenue. Those sales ...
Y-mAbs Therapeutics (NASDAQ:YMAB) stock peaked at $54.1 in late 2020, fueled by high hopes for its cancer treatment, Omburtamab. However, the FDA's 2020 Refusal to File and subsequent Complete ...
During the last three months, 5 analysts shared their evaluations of Y-mAbs Therapeutics (NASDAQ:YMAB), revealing diverse outlooks from bullish to bearish. In the table below, you'll find a summary of ...
(RTTNews) - Y-mAbs Therapeutics (YMAB) and Nobelpharma have entered into a license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of ...
Researchers performed a meta-analysis of randomized trial studies that compared the use of amyloid-reducing monoclonal antibodies (MABs) in patients with Alzheimer dementia at a dose consistent with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results